Table 2.
Completed Phase I clinical trials with in vivo stimulation of gamma delta T cells. RCC: renal cell carcinoma, CRC: colorectal cancer. NHL: Non Hodgkins Lymphoma, MM: Multiple myeloma. OR: Overall Response. SD: stable disease. PR: partial response. AML: acute myeloid leukemia. Peripheral Blood Lymphocytes (PBL)
| Reference | Indication | Treatment | n= | Response | Response Biomarker |
|---|---|---|---|---|---|
| [112] | Hematological (NHL + MM) |
Pamidronate + IL-2 | 19 | 3 SDs | Vγ9Vδ2 PBL |
| [89] | Prostate Cancer | Zoledronate/Zoledronate + IL-2 | 18 | 1 SD, 1 PR 4 SD, 2 PR |
TRAIL, Vγ9Vδ2 PBL |
| [115] | RCC, CRC, Breast Cancer | BrHPP + IL-2 | 28 | ||
| [88] | Breast Cancer | Zoledronate + IL-2 | 10 | 2 SD, 1 PR | Vγ9Vδ2 PBL |
| [113] | Metastatic RCC | Zoledronate + IL-2 | 12 | Vγ9Vδ2 PBL | |
| [116] | RCC, melanoma, AML | Zoledronate + IL-2 | 21 | 0 in solid tumors, 2 PR in AML | IFN-γ and in vivo expansion |
| [117] | Refractory neuroblastoma | Zoledronate + IL-2 | 4 | 1 SD | Vγ9Vδ2 PBL |